AstraZeneca (NYSE:AZN) updated its FY18 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $3.30-3.50 for the period, compared to the Thomson Reuters consensus estimate of $3.46.
A number of brokerages have recently commented on AZN. ValuEngine lowered AstraZeneca from a strong-buy rating to a buy rating in a report on Wednesday, May 2nd. Zacks Investment Research lowered AstraZeneca from a hold rating to a sell rating in a report on Monday, April 9th. BMO Capital Markets set a $40.00 price target on AstraZeneca and gave the stock a buy rating in a report on Thursday, March 22nd. Jefferies Group upgraded AstraZeneca from a hold rating to a buy rating and upped their price target for the stock from $28.43 to $36.70 in a report on Monday, March 19th. Finally, Leerink Swann upped their price target on AstraZeneca from $36.00 to $38.00 and gave the stock a market perform rating in a report on Tuesday, February 6th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $38.12.
Shares of NYSE AZN opened at $36.44 on Friday. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62. The firm has a market capitalization of $92.45 billion, a P/E ratio of 8.51, a PEG ratio of 1.94 and a beta of 0.61. AstraZeneca has a one year low of $36.35 and a one year high of $36.55.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.